Screener
Jazz Pharmaceuticals JAZZ EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income tax expense (benefit) | 6.1 | (17.8) |
| Equity in loss of investees | — | 0.5 |
| Net income (loss) | $293.1 | $(92.5) |
| Net income (loss) per ordinary share: | ||
| Basic | $4.73 | $(1.52) |
| Diluted | $4.43 | $(1.52) |
| Weighted-average ordinary shares used in per share calculations - basic | 61.9 | 61.0 |
| Weighted-average ordinary shares used in per share calculations - diluted | 66.1 | 61.0 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's EPS (diluted)?
- Jazz Pharmaceuticals (JAZZ) reported EPS (diluted) of $4.43 in Q1 2026.
- How has Jazz Pharmaceuticals's EPS (diluted) changed year-over-year?
- Jazz Pharmaceuticals's EPS (diluted) increased by 391.4% year-over-year, from -$1.52 to $4.43.
- What is the long-term trend for Jazz Pharmaceuticals's EPS (diluted)?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's EPS (diluted) has grown at a 17.1% compound annual growth rate (CAGR), from -$5.42 to $8.70.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Jazz Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude